A breakthrough study on the anti-photodamage effects of Gardenia Fructus Extracts, jointly conducted by Hangzhou CIRS KEXIN Biotech Co., Ltd. (CIRS Biotech) and Shanghai Junyu Biotechnology Co., Ltd. (Junyu Group), has been published in Cosmetics, an internationally renowned SCI-indexed journal. The breakthrough study provides scientific validation for the development of photoprotective ingredients and the establishment of its efficacy evaluation systems.

Utilizing a multidisciplinary methodology integrating in vitro efficacy assessment, proteomics, and network pharmacology, this research elucidates the anti-photodamage mechanisms of Gardenia Fructus Extract. The extract demonstrably mitigates UVB-induced photodamage through multipathway regulation: enhancing antioxidant defenses, suppressing inflammatory cascades, accelerating barrier restoration, and modulating cell cycle progression (specifically via G2/M checkpoint control and p53 signaling). Geniposin was established as the primary bioactive constituent. This work provides an evidence-based paradigm for screening natural photoprotective cosmetic ingredients.

As a professional third-party research institution, CIRS Biotech devotes itself to providing scientific validation for cosmetic efficacy claims to cosmetics and ingredients companies. It has established comprehensive technical systems across core efficacy evaluation domains—including whitening, anti-aging, and sensitive skin solutions—delivering one-stop solutions, from ingredient screening and in vitro efficacy evaluation to product development testing and technical consulting. Junyu Group, a leader in beauty and health sciences, leverages core expertise in plant extract bioactivity an